Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7840693 | 0.90 | KDM4E (0.57) | CTSVCTSLKDM4EPDCD1CD274 | |
| Hydrochloric Acid SCHEMBL11669913 | 0.89 | KDM4E (0.56) | CTSVCTSLKDM4EPDCD1CD274 | |
| Bromide SCHEMBL11670771 | 0.89 | KDM4E (0.56) | CTSVCTSLKDM4EPDCD1CD274 | |
| SCHEMBL4290434 | 0.85 | POLB (0.55) | CTSVCTSLPDCD1CD274POLB | |
| SCHEMBL4126272 | 0.83 | CTSV (0.58) | CTSVCTSLPDCD1CD274POLB | |
| SCHEMBL3994909 | 0.83 | POLB (0.56) | CTSVCTSLPDCD1CD274POLB | |
| SCHEMBL10409125 | 0.83 | POLB (0.56) | CTSVCTSLPOLBMEN1KMT2A | |
| SCHEMBL30008070 | 0.83 | POLB (0.56) | CTSVCTSLPDCD1CD274POLB | |
| SCHEMBL30008652 | 0.83 | CTSV (0.58) | CTSVCTSLPDCD1CD274POLB | |
| SCHEMBL27792044 | 0.83 | POLB (0.56) | CTSVCTSLPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101321743-A | 1,1, 3-trioxo-1, 2, 5-thiadiazolidines as PTP-enzyme inhibitors and their use | NOVARTIS AG (CH) | 2008-12-10 | — | — | CN | disclosed |
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1960377-A1 | l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS | Novartis AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007067614-A1 | l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | PTPRS, IRS1, PTPMT1 | CTSV 3535/4885CTSL 3846/4885KDM4E 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.